Reishi D. International Inc.'s references in labeling and other text to "traditional Chinese medicine" and other claims for its namesake dietary supplements renders the products unapproved new drugs, FDA's Office of Regulatory Affairs San Francisco District said in a Feb. 7 warning letter. The warning, which followed an April 2017 inspection at the firm's facility in South San Francisco and a review of its labels and packages for its products, also detailed good manufacturing practice regulation violations as well as misbranding problems. In addition to references to TCM, violative claims for Reish D. brand supplements included bees "use propolis to protect themselves from bacteria and diseases" and propolis "contains more than 30 different flavonoids and antioxidants to help control free radicals," according to the letter.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on HBW Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?